Endocannabinoid 1 and 2 (CB(1); CB(2)) receptor agonists affect negatively cow luteal function in vitro.
Thirty to 40% of pregnancies are lost during the first third of pregnancy, which has been hypothesized to be due to inadequate progesterone secretion by the corpus luteum. Loss of luteal progesterone secretion during the estrous cycle is via uterine secretion of prostaglandin F(2)alpha (PGF(2)alpha). Cow luteal tissue secretion of prostaglandins (PG) E (PGE(1)+PGE(2)) and PGF(2)alpha are derived from precursors in membrane phospholipids. Cow luteal tissue secretion of PGE and PGF(2)alpha increased linearly with time in culture with the PGE: ratio being 1:1. PGE(1) or PGE(2) are luteotropic in cows and ewes and antiluteolytic in vitro and in vivo in ewes. Endocannabinoids are also derived from phospholipids and are associated with infertility, presumably by reducing implantation; however, effects of endocannabinoids on luteal function have not been addressed. The objective of this experiment was to determine the effects of endocannabinoid type 1 and 2 receptor agonists and receptor antagonists or a fatty acid amide hydrolase (FAAH; catabolizes endocannabinoids) inhibitor, PGE(1), or PGF(2)alpha on bovine luteal secretion of progesterone, PGE, and PGF(2)alphain vitro. PGE and PGF(2)alpha was increased (P< or =0.05) with time in culture, while progesterone did not change (P> or =0.05) with time in vehicle-treated luteal slices in vitro. Progesterone was increased (P< or =0.05) by PGE(1) and decreased (P< or =0.05) by PGF(2)alpha, CB(1) or CB(2) receptor agonists, or a FAAH inhibitor. Both PGE and PGF(2)alpha were decreased (P< or =0.05) by CB(1) or CB(2) receptor agonists or a FAAH inhibitor when compared to vehicle controls. It is concluded that endocannabinoid receptor agonists negatively affect cow luteal function in vitro and that the corpus luteum may also be a site for endocannabinoid decreased fertility as well as a reduction in implantation.
Weems
Y S
YS
University of Hawaii, Department of Human Nutrition, Food, and Animal Sciences (HNFAS), 1955 East-West Road, Honolulu, HI 96822, USA.
Lewis
A W
AW
Neuendorff
D A
DA
Randel
R D
RD
Weems
C W
CW
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000241:Adenosine / Q000031:analogs & derivatives; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D002417:Cattle / Q000502:physiology*; D003338:Corpus Luteum / Q000187:drug effects* / Q000502:physiology; D015237:Dinoprost / Q000502:physiology; D015232:Dinoprostone / Q000502:physiology; D005260:Female; D066298:In Vitro Techniques; D007211:Indoles / Q000494:pharmacology; D063065:Organophosphonates / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011720:Pyrazoles / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology; D011897:Random Allocation; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists*; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists*
D001095:Arachidonic Acids; D007211:Indoles; D063065:Organophosphonates; D010880:Piperidines; D011720:Pyrazoles; D011759:Pyrrolidines; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; C119324:arachidonylcyclopropylamide; C104810:methyl arachidonylfluorophosphonate; C103505:AM 251; D011374:Progesterone; D015237:Dinoprost; D000225:Adenine; D000241:Adenosine; D015232:Dinoprostone; C517546:galidesivir; C094023:iodopravadoline